Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
Portfolio Pulse from Vandana Singh
AstraZeneca's Phase 3 trial of datopotamab deruxtecan (Dato-DXd) for breast cancer did not achieve statistical significance in overall survival, though it showed improvement in progression-free survival and patient-reported outcomes. The safety profile was consistent with previous analyses. AstraZeneca's stock is down 1.86% in premarket trading.
September 23, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca's Phase 3 trial of Dato-DXd for breast cancer failed to achieve statistical significance in overall survival, impacting its stock price negatively. The safety profile remains consistent, but the trial's results may affect investor sentiment.
The failure to achieve statistical significance in overall survival for Dato-DXd in the Phase 3 trial is a setback for AstraZeneca, likely leading to negative investor sentiment and a drop in stock price. The consistent safety profile is a positive, but the primary endpoint miss overshadows this.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100